CN106138194B - A kind of compound Chinese medicinal preparation for treating hyperuricemia and preparation method thereof - Google Patents
A kind of compound Chinese medicinal preparation for treating hyperuricemia and preparation method thereof Download PDFInfo
- Publication number
- CN106138194B CN106138194B CN201610562805.4A CN201610562805A CN106138194B CN 106138194 B CN106138194 B CN 106138194B CN 201610562805 A CN201610562805 A CN 201610562805A CN 106138194 B CN106138194 B CN 106138194B
- Authority
- CN
- China
- Prior art keywords
- preparation
- sophora flower
- walnut kernel
- medicine
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 150000001875 compounds Chemical class 0.000 title claims abstract description 18
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 14
- 241000219784 Sophora Species 0.000 claims abstract description 40
- 239000003814 drug Substances 0.000 claims abstract description 40
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 37
- 235000020234 walnut Nutrition 0.000 claims abstract description 37
- 239000000463 material Substances 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- 239000000284 extract Substances 0.000 claims description 38
- 241000758789 Juglans Species 0.000 claims description 36
- 239000007788 liquid Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 239000011805 ball Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 240000007049 Juglans regia Species 0.000 abstract 1
- 231100001231 less toxic Toxicity 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 26
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 25
- 229940116269 uric acid Drugs 0.000 description 25
- 241000700159 Rattus Species 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 238000000605 extraction Methods 0.000 description 14
- 238000009835 boiling Methods 0.000 description 9
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000628997 Flos Species 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 208000000913 Kidney Calculi Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010029148 Nephrolithiasis Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229960002529 benzbromarone Drugs 0.000 description 3
- -1 flavone compound Chemical class 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- PQGCEDQWHSBAJP-TXICZTDVSA-N 5-O-phosphono-alpha-D-ribofuranosyl diphosphate Chemical compound O[C@H]1[C@@H](O)[C@@H](O[P@](O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O PQGCEDQWHSBAJP-TXICZTDVSA-N 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101800000628 PDH precursor-related peptide Proteins 0.000 description 2
- 206010038419 Renal colic Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 2
- 229960003199 etacrynic acid Drugs 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- FXLJDRXREUZRIC-BAOOBMCLSA-N (3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO FXLJDRXREUZRIC-BAOOBMCLSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000255964 Pieridae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CPWPJLJWUXOOAB-UHFFFAOYSA-N benzene;bromine Chemical compound [Br].C1=CC=CC=C1 CPWPJLJWUXOOAB-UHFFFAOYSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229950002752 oxipurinol Drugs 0.000 description 1
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of compound Chinese medicinal preparation for treating hyperuricemia and preparation method thereof.It is characterized in that the Chinese medicine material medicine that it is matched by following weight is prepared：Sophora flower 5~10, walnut kernel 2~6, compound Chinese medicinal preparation of the invention have it is curative for effect, convenient to take, treat both principal and secondary aspect of disease, be integrally-regulated, less toxic side effect and other advantages.
Description
Technical field
The invention belongs to food, health products, medicine and medical field, and in particular to a kind of Chinese medicine for treating hyperuricemia
Compound, and the preparation method of its extract and preparation.
Technical background
Hyperuricemia is a kind of common metabolic disease, and the incidence of disease actively develops antihyperuricemic in ascendant trend year by year
The preventing and treating of disease and its complication has turned into the focus of current medical field research.Traditional Chinese medicine prevention gout has long history, warp
Thousands of years of clinical practice is crossed, have accumulated abundant medical experience, and forms the theoretical system and treatment method of system.We
Come from《Compendium of Materia Medica》(draw《Hospital makes a summary》), in side sophora flower it is micro- fry, two liang of walnut kernel, the clock of wine without lime one.Decoct over thousands of boiling, heat
Clothes.Controlling furuncle swelling toxin ..., Dan inflammation pain persons all control.It is main in discovery side according to modern study document analysis ancient prescription Chinese traditional medicine thing composition
Composition is based on flavone compound, and modern study proves, flavone compound can be prevented by number of mechanisms, multiple target spots
Control high lithemia and gout.
Understanding of the modern medicine to hyperuricemia：A source part for uric acid is to decompose generation through enzyme by the purine in food
Thank (exogenous), another part is decomposed (interior by the nucleic acid of internal cell catabolism and other purine compounds
Source property).The excretion pathway of uric acid is mainly drained by kidney.Normally produce uric acid about 750mg or so daily for each person, its
In 1/3 discharged with urine, 1/3 is drained by enteron aisle or is bacterially decomposed in enteron aisle.When imbalance occurs in above uric acid metabolism
Abnormality, you can cause hyperuricemia.
Understanding of the traditional Chinese medical science to complication such as gouts caused by high lithemia：The cause of disease is mostly overfeeding greasy and surfeit flavour, the dysfunction of the spleen in transport or
Insufficiency of natural endowment, kidney ascending the clear and descending the turbid mistake department is so that raw in damp and hot turbid poison, and simultaneous wet heresy of catching cold, and attacks channels and collaterals, QI-blood circulation
It is not smooth.The interpretation of the cause, onset and process of an illness is that the turbid numbness of wet hot phlegm hinders channels and collaterals, not general rule pain.With the horizontal raising of the modern life, people suffer from high lithemia and caused
The reason for goat is due to more food delicious food more, is negligent of working, belongs to the beriberoid pyretic arthralgia in traditional Chinese medical science bi Zheng greatly.Medication：Mainly
Concentrate in the utilization of tonic, drug for invigorating blood circulation and eliminating stasis, antipyretic, damp-clearing drug and the aspect of drugs for dispelling internal cold five.
Clinical conventional uricosuric is currently used at present following three kinds：(1) benemid (sulphurs of probenicid third
Relax)：The main renal tubule that suppresses causes ethacrynic acid to act on the re-absorption of uric acid.Draw to have when preventing uric acid from largely being discharged from kidney
The side effect of kidney damage and kidney stone is played, about 5% patient occurs fash, heating, stomach stimulation, renal colic and evokes acute hair
The side effects such as work.(2) sulfinpyrazone (sulfinpyrazone)：The derivative of Phenylbutazone, suppress renal tubule to uric acid again
Absorb, uricotelism is strong compared with probenecid, and this medicine has stimulation to gastric mucosa, and ulcer patient uses with caution.(3) Benzbromarone
(benzbromarone)：For strong ethacrynic acid medicine, in Europe extensively using having for many years, toxic action is slight, does not influence
Hepatic and renal function, fash, heating seldom occurs, but can have intestines and stomach reaction, renal colic and excite acute arthritis to break out.
Suppress uric acid synthetic drug to there was only different purine alcohol (allopurinol) so far, this medicine can suppress xanthine
Oxidizing ferment, prevents hypoxanthine and xanthine from being converted into uric acid, and itself is then aoxidized gradually in human body, and generation is soluble in water
Different xanthine (oxipurinol) through urine ejection, and corresponding nucleotide can be transformed into the presence of PRPP, consume PRPP, also
PRPPAT can be suppressed, reduce IMP synthesis, thus serum Uric Acid Concentration can be reduced rapidly, suppress tophus and kidney calculus urate
Synthesis, and promote tophus to dissolve.Individuals patients can have heating, allergic rash, stomachache, diarrhoea, leucocyte and blood platelet to subtract
Few, the even side effect such as hepatic disorder, being discontinued and give corresponding treatment can generally recover, and occasionally necrosing property dermatitis is then
It is in a bad way, should is to rescue.
To sum up, conventional anti-trioxypurine medicine clinical at present has certain side effect, and medicinal material used is middle traditional Chinese medicines in we
Allusion quotation records kind, and the medicinal and edible varieties announced for food Bureau of Drugs Supervision of country, and security can be exempted to do in new drug research, it is contemplated that
Its safety and effectiveness is the sharpest edges of clinical application.
The purpose of the present invention be just to provide for it is a kind of treat both principal and secondary aspect of disease, integrally-regulated and low toxic side effect anti-trioxypurine Chinese medicine
Compound and its preparation.
The content of the invention
The present invention provides a kind of compound Chinese medicinal preparation for treating hyperuricemia, during the preparation is matched by following weight
Medicine bulk drug is prepared：Sophora flower 5~10, walnut kernel 2~6.Preferably, the Chinese medicine material that the preparation is matched by following weight
Medicine is prepared：Sophora flower 10, walnut kernel 1~5.It is furthermore preferred that prepared by the Chinese medicine material medicine that the preparation is matched by following weight
Form：Sophora flower 10, walnut kernel 2~4.The Chinese medicine material medicine that the most preferred preparation is matched by following weight is prepared：Chinese scholartree
10 are spent, walnut kernel 2.
Compound preparation of the present invention, it is medicine, food or the acceptable any formulation of health products.The formulation choosing
From：Liquid preparation, tablet, capsule, granule, pill, pill, powder, paste.The formulation contains auxiliary material if necessary,
The auxiliary material is selected from：Microcrystalline cellulose, starch, dextrin, sucrose, stachyose, sodium carboxymethyl starch, low substituted hydroxy-propyl fiber
Element, polyethylene glycol, polyvinylpyrrolidone, talcum powder, magnesium stearate, sorbitan mono-oleic acid ester, glycine, gelatin, glycerine,
Water, ethyl-para-hydroxybenzoate.
The present invention further provides the preparation method of the compound Chinese medicinal preparation of the present invention, methods described is selected from
(1) water extraction method：Sophora flower, walnut kernel are taken, adds 5~15 times of amount water, decocts 2~3 times, 0.5~2 hour every time, closes
And decocting liquid, filtration, the thick paste that relative density is 1.30~1.35 (60 DEG C) is concentrated under reduced pressure into, is dried in vacuo, crushes, obtains dry extract
Powder；
(2) alcohol extracting is followed the example of：Sophora flower, walnut kernel are taken, adds 5~15 times of 30~90% ethanol of amount to extract 2~3 times, every time 0.5~
2 hours, merge extract solution, filtration, be concentrated under reduced pressure into the thick paste that relative density is 1.30~1.35 (60 DEG C), vacuum drying, powder
It is broken, obtain dry extract.
The present invention further comprises that described compound Chinese medicinal preparation is preparing treatment hyperuricemia or diseases related：Bitterly
Application in wind arthritis, gouty renal lesions, gouty kidney stone, gouty heart disease, gouty hypertension drug.
In the present invention, sophora flower, sophora flower is preferably fried, there is the effect of clearing heat and promoting diuresis, cooling blood and hemostasis, the heat that can be purified the blood point.Core
Peach kernel, property is warm but not dry, energy benefiting qi and nourishing blood, the strong body of strengthening the essence, qualcomm meridian, moistens blood vessels.Two medicine phases 5, the rheumatic fever of channels and collaterals can be searched
Poison, all controlled so as to treat furuncle swelling toxin , Dan inflammation pain persons.
Illustrate beneficial effects of the present invention below by way of experimental data
It is prepared as follows sophora flower, walnut kernel dry extract；And pharmacological experiment study is carried out, its pharmacological experiment study result
It is as follows：
1. test the preparation of medication：
Sophora flower 500g is taken, adds 9 times of 30% ethanol of amount to decoct 2 times, extracts 2 hours, collecting decoction, filtration, subtract after boiling every time
Pressure is concentrated into the thick paste that relative density is 1.30~1.35 (60 DEG C), is dried in vacuo, and crushes, and crosses 20 mesh sieves, obtains sophora flower dry extract
Powder.
Sophora flower walnut kernel 500g is taken, adds 9 times of 30% ethanol of amount to decoct 2 times, is extracted 2 hours after boiling every time, collecting decoction, filter
Cross, be concentrated under reduced pressure into the thick paste that relative density is 1.30~1.35 (60 DEG C), be dried in vacuo, crush, cross 20 mesh sieves, obtain walnut kernel
Dry extract.
Sophora flower 500g, walnut kernel 50g are taken, adds 9 times of 30% ethanol of amount to decoct 2 times, is extracted 2 hours after boiling every time, merge and decoct
Liquid, filtration, the thick paste that relative density is 1.30~1.35 (60 DEG C) is concentrated under reduced pressure into, is dried in vacuo, is crushed, 20 mesh sieves is crossed, obtains
Sophora flower+walnut kernel (10:1) dry extract.
Sophora flower 500g, walnut kernel 100g are taken, adds 9 times of 30% ethanol of amount to decoct 2 times, is extracted 2 hours after boiling every time, merge and decoct
Liquid, filtration, the thick paste that relative density is 1.30~1.35 (60 DEG C) is concentrated under reduced pressure into, is dried in vacuo, is crushed, 20 mesh sieves is crossed, obtains
Sophora flower+walnut kernel (10:2) dry extract.
Sophora flower 500g, walnut kernel 200g are taken, adds 9 times of 30% ethanol of amount to decoct 2 times, is extracted 2 hours after boiling every time, merge and decoct
Liquid, filtration, the thick paste that relative density is 1.30~1.35 (60 DEG C) is concentrated under reduced pressure into, is dried in vacuo, is crushed, 20 mesh sieves is crossed, obtains
Sophora flower+walnut kernel (10:4) dry extract.
2. pharmacological experiment study：
2.1 packets and administration：
Research is only tested from male SD rat 80.It is divided into normal group, model group by body weight stratified random.Normal group
(10) give full diet, drinking-water；Model group (70) give full diet and 10% fructose water.After modeling success, model
Group rat is randomly divided into Benzbromarone comparison medicine group, Flos Sophorae extract group, Semen Juglandis extract group, sophora flower+walnut kernel (10:1)
Extract group, sophora flower+walnut kernel (10:2) extract group, sophora flower+walnut kernel (10:4) extract group, every group 10.Administration phase
Between each treatment group continue to give 10% modeling feed.
Normal group, model group give 0.5%CMC-Na aqueous solution gavages, and remaining group is dissolved in 0.5%CMC- by relative medicine
Na (ultrasonic dissolution) gastric infusion, influence of the different parts extract to rat uric acid level, administered volume 1ml/ are observed respectively
100g body weight, daily gavage once, are administered 21 days.Weigh within every 7 days the weight of animals, biochemical process detection serum uric acid level.
The experiment packet of table 1 and number of animals
Medication：
Method of administration:Gastric infusion (consistent with the clinical plan route of administration of people).
Administered volume:1ml/100g body weight.
Administration time：There is therapeutic after hyperuricemia in rat, and the daily morning presses body weight gavage 1 time.
The time limit is administered：Successive administration 14 days.
Test sample is prepared：Matching while using, a certain amount of herbal mixture component is weighed, add 0.5% CMC- of respective volume
Na solution, ultrasound, is stirred and evenly mixed rear standby.
Test sample is given：Decoction is extracted with disposable syringe, by document《Rat hyperuricemia syndrome manifestations feature and
The intervention study of witloof》Operated.
2.2 Testing index
Every 7 days animals are weighed once.Blood is taken during modeling and during administration once within every 7 days, centrifuges serum.It is biochemical
It is horizontal to detect serum uric acid (UA).
2.3 results count and analysis
As a result represented with means standard deviationBody weight and Biochemical Indices In Serum count soft with SPSS 17.0 respectively
Part calculates every group of average value and standard deviation and carries out ANOVA variance analyses.
The horizontal change of serum uric acid (UA)：Compared with normal group, modeling the 7th, 14,21,28 days model group rats serum UA
Horizontal significantly rise (P<0.05).
With model group ratio, the 7th day Benzbromarone group rat blood serum UA level of administration is in reduction trend, and the 14th day benzene bromine is administered
Grand group of rat blood serum UA of horse significantly reduces (P<0.05)；The 7th day Flos Sophorae extract group, Semen Juglandis extract and compatibility 1 is administered to carry
It is in reduction trend to take thing group rat blood serum UA levels, but has no significant difference (P ＞ 0.05)；14 days Flos Sophorae extract groups are administered
And the extract group rat blood serum UA levels of compatibility 1 significantly reduce (P<0.05)；The 7th day, 14 days extract groups of compatibility 2 and compatibility is administered
3 extract group rat blood serum UA levels significantly reduce (P<0.05).Concrete outcome is shown in Table 2, table 3：
During table 2, modeling rat blood serum UA it is horizontal (μmol/L)
Note：# compares P with normal group<0.05
During table 3, administration rat blood serum UA it is horizontal (μm ol/L, n=12)
Note：# compares P with normal group<0.05；
* P is compared with model group<0.05, * * compares P with model group<0.01
Conclusion：Under this experiment condition, -21 days the 7th day model group rats serum uric acid levels of modeling are significantly higher than normally
Group rat, hyperuricemia model mould success.7,14 days compatibilities 2 of administration and the extract group of compatibility 3 have lasting anti-trioxypurine to make
With.Simple sophora flower shows notable anti-trioxypurine effect in the talent of administration the 14th, and simple walnut kernel anti-trioxypurine acts on unobvious.
Show that sophora flower, Semen Juglandis extract can significantly improve drug effect after carrying out compatibility, played significant synergy.
Embodiment
[embodiment 1] alcohol extraction procedure
1st, individually extraction：
Sophora flower 100g is taken, adds 9 times to measure 30% ethanol heating extraction 2 times, is extracted 2 hours after boiling every time, merges extract solution, filter
Cross, reclaim ethanol, be concentrated under reduced pressure into the thick paste that relative density is 1.30~1.35 (60 DEG C), be dried in vacuo, crush, obtain sophoranl
Promote extract powder 37g, paste-forming rate 35-40%.
Walnut kernel 100g is taken, is smashed to pieces, adds 9 times to measure 30% ethanol heating extraction 2 times, is extracted 2 hours after boiling every time, merging carries
Liquid is taken, is filtered, reclaims ethanol, the thick paste that relative density is 1.30~1.35 (60 DEG C) is concentrated under reduced pressure into, is dried in vacuo, crush,
Obtain walnut kernel alcohol extracting dry extract 12g, paste-forming rate 10-15%.
2nd, mixing extraction：
Sophora flower 100g, walnut kernel 20g are taken, adds 9 times of 30% ethanol of amount to extract 2 times, is extracted 2 hours after boiling every time, merging carries
Liquid is taken, is filtered, reclaims ethanol, the thick paste that relative density is 1.30~1.35 (60 DEG C) is concentrated under reduced pressure into, is dried in vacuo, crush,
Obtain sophoranl and promote extract powder 41g, paste-forming rate 33-38%.
[embodiment 2] water extracting method
1st, individually extraction：
Sophora flower 100g is taken, adds 9 times of amount decoctings to boil 2 times, 2 hours every time, collecting decoction, filtration, is concentrated under reduced pressure into relatively close
Spend for the thick paste of 1.30~1.35 (60 DEG C), be dried in vacuo, crush, obtain sophora flower water extraction dry extract 42g, paste-forming rate 35-
40%.
Walnut kernel 100g is taken, is smashed to pieces, adds 9 times of amount decoctings to boil 2 times, 2 hours every time, collecting decoction, filtration, is concentrated under reduced pressure into
Relative density is the thick paste of 1.30~1.35 (60 DEG C), is dried in vacuo, and crushes, obtains walnut kernel water extraction dry extract 8g, paste-forming rate
For 7-12%.
2nd, mixing extraction：
Sophora flower 100g, walnut kernel 20g are taken, adds 9 times of amount decoctings to boil 2 times, 2 hours every time, collecting decoction, filtration, depressurizes dense
The thick paste that relative density is 1.30~1.35 (60 DEG C) is reduced to, is dried in vacuo, is crushed, is obtained sophora flower water extraction dry extract 45g, go out cream
Rate is 35-40%.
The preparation of [embodiment 3] liquid preparation
The ㎏ of sophora flower 25, the ㎏ of walnut kernel 5 are taken, is extracted 2 times with 9 times of 30% ethanol of amount, extraction 2 hours, merge extract solution every time,
100 liters are concentrated under reduced pressure into, adds the ㎏ of honey 2, is mixed, filtration, produces oral liquid.
It is prepared by [embodiment 4] solid beverage
The ㎏ of sophora flower 25, the ㎏ of walnut kernel 10 are taken, is extracted 2 times with 9 times of 30% ethanol of amount, extraction 2 hours, merge extraction every time
Liquid, filtration, add the ㎏ of milk powder 8, the ㎏ of sucrose 2 to mix, be concentrated under reduced pressure into (60 DEG C) Zuo You of density 1.10, be spray-dried, fill aluminium plastic bag,
Every bag of 3g, produces solid beverage.
It is prepared by [embodiment 5] granule
Take sophora flower water extract 15g, walnut kernel water extract 5g to mix, add dextrin 15g, wood Icing Sugar 10g, mix, use
Particle is made in 90% appropriate amount of ethanol, dries, whole grain, produces granule.
The preparation of [embodiment 6] tablet
The ㎏ of sophora flower 25, the ㎏ of walnut kernel 15 are taken, is extracted 2 times with 9 times of 30% ethanol of amount, extraction 2 hours, merge extraction every time
Liquid, filter, concentration, add starch, dextrin, Icing Sugar prepares particle, and tabletting produces tablet.
The preparation of [embodiment 7] capsule
The ㎏ of sophora flower 25, the ㎏ of walnut kernel 2.5 are taken, is extracted 2 times with 9 times of 30% ethanol of amount, extraction 2 hours, merge extraction every time
Liquid, filter, concentration, add starch, dextrin, Icing Sugar, prepare particle, it is encapsulated to produce capsule.
Claims (8)
1. a kind of compound Chinese medicinal preparation for treating hyperuricemia, it is characterised in that during the preparation is matched by following weight
Medicine bulk drug is prepared：Sophora flower 10, walnut kernel 1~5.
2. compound preparation as claimed in claim 1, it is characterised in that the Chinese medicine material medicine that the preparation is matched by following weight
It is prepared：Sophora flower 10, walnut kernel 2~4.
3. compound preparation as claimed in claim 1, it is characterised in that the Chinese medicine material medicine that the preparation is matched by following weight
It is prepared：Sophora flower 10, walnut kernel 2.
4. compound preparation as claimed in claim 1, it is pharmaceutically acceptable any formulation.
5. compound preparation as claimed in claim 1, the formulation is selected from：Liquid preparation, tablet, capsule, granule, ball
Agent, powder.
6. compound preparation as claimed in claim 1, it is characterised in that also contain auxiliary material, the auxiliary material is selected from：Microcrystalline cellulose
Element, starch, dextrin, sucrose, stachyose, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, polyethylene glycol, polyvinyl pyrrole
Alkanone, talcum powder, magnesium stearate, sorbitan mono-oleic acid ester, glycine, gelatin, glycerine, water or ethyl-para-hydroxybenzoate.
7. compound preparation preparation method as claimed in claim 1, it is characterised in that：Methods described is selected from
(1) water extraction method：Sophora flower, walnut kernel are taken, adds 5~15 times of amount water, is decocted 2~3 times, 0.5~2 hour every time, is merged and decoct
Liquid, filtration, is concentrated under reduced pressure, and the thick paste that 60 DEG C of measure relative densities are 1.30~1.35, is dried in vacuo, crushes, obtain dry extract；
(2) alcohol extracting is followed the example of：Sophora flower, walnut kernel are taken, adds 5~15 times of 30~90% ethanol of amount to extract 2~3 times, 0.5~2 is small every time
When, merge extract solution, filtration, be concentrated under reduced pressure, the thick paste that 60 DEG C of measure relative densities are 1.30~1.35, be dried in vacuo, crush,
Obtain dry extract.
8. application of the compound preparation in the medicine for preparing treatment hyperuricemia described in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610562805.4A CN106138194B (en) | 2016-07-16 | 2016-07-16 | A kind of compound Chinese medicinal preparation for treating hyperuricemia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610562805.4A CN106138194B (en) | 2016-07-16 | 2016-07-16 | A kind of compound Chinese medicinal preparation for treating hyperuricemia and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106138194A CN106138194A (en) | 2016-11-23 |
| CN106138194B true CN106138194B (en) | 2018-04-03 |
Family
ID=58059266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610562805.4A Active CN106138194B (en) | 2016-07-16 | 2016-07-16 | A kind of compound Chinese medicinal preparation for treating hyperuricemia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106138194B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107259006A (en) * | 2017-06-19 | 2017-10-20 | 黎金莲 | A kind of bamboo juice leaf of bamboo health protection tea for treating gout |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181345A (en) * | 2007-11-15 | 2008-05-21 | 南京大学 | Application of flos Sophora chromocor extract in the preparation of medicament for restrainting uric acid transporter URAT1 |
| CN102965252A (en) * | 2012-11-19 | 2013-03-13 | 青岛本草生物科技有限公司 | Healthcare wine for gout |
-
2016
- 2016-07-16 CN CN201610562805.4A patent/CN106138194B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181345A (en) * | 2007-11-15 | 2008-05-21 | 南京大学 | Application of flos Sophora chromocor extract in the preparation of medicament for restrainting uric acid transporter URAT1 |
| CN102965252A (en) * | 2012-11-19 | 2013-03-13 | 青岛本草生物科技有限公司 | Healthcare wine for gout |
Non-Patent Citations (1)
| Title |
|---|
| 槐花的营养保健功能及食品开发前景;钱文文等;《农产品加工》;20160930(第9期);第59-61页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106138194A (en) | 2016-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007006203A1 (en) | A capsule formulation for treating hypertension and coronary heart disease and process for preparation thereof | |
| WO2007009291A1 (en) | A pharmaceutical composition of traditional chineses medicine for treating rheumatoid arthritis and preparation thereof | |
| CN101264205A (en) | Chinese medicinal composition for treating gout and preparation thereof | |
| CN103623341A (en) | Drug for treating hypertension and cardiovascular and cerebrovascular diseases caused by hypertension | |
| CN101264217A (en) | Chinese medicine assembly for nourishing yin and tonifying kidney, promoting qi and promoting blood circulation, and relaxing tendons and collaterals | |
| JP2002154979A (en) | Medicine composition for i type allergy and method for producing the same | |
| CN102671060B (en) | Medicinal composition for treating gout and preparation method thereof | |
| CN104825788A (en) | Application of traditional Chinese medicine composition in preparation of drug for treating transient ischemic attack | |
| CN101461932B (en) | Medicament composition for treating children's damp-heat diarrhea induced by spleen insufficiency and preparation method thereof | |
| CN101574476B (en) | Medicinal material composition used for lowering lipid and protecting liver auxiliarily | |
| CN101011562A (en) | Novel formulation of shenqiwendan decoction and production method thereof | |
| CN102488838B (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN106138194B (en) | A kind of compound Chinese medicinal preparation for treating hyperuricemia and preparation method thereof | |
| CN104721467B (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and application thereof | |
| CN102293928A (en) | Chinese medicinal composition for treating hyperuricemia and urarthritis, and preparation method and application thereof | |
| CN114747766A (en) | Health-care food composition capable of reducing uric acid and preparation method and application thereof | |
| CN105999058B (en) | Bidens bipinnata lipid-lowering tablet | |
| CN103230552B (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN102526631A (en) | Traditional Chinese medicine preparation, tablet and capsule for curing dilated cardiomyopathy and preparation method | |
| CN102048966A (en) | Chinese medicinal preparation for treating diabetes and preparation method thereof | |
| CN104887766A (en) | Traditional Chinese medicine compound capsules for treating atherosclerosis and preparation method thereof | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN108379379A (en) | Chinese medicine composition for acute stage of gout | |
| CN107029124A (en) | It is a kind of to be used to treat Chinese medicine composition of essential hypertension and preparation method thereof | |
| CN102727672B (en) | A kind of Chinese medicine composition for the treatment of hypertensive nephropathy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |